SRS
8
3
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Measuring and Mapping Cognitive Decline After Brain Radiosurgery
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Impact of Curve Magnitude on Pain and Body Image in Patients With Adolescents Idiopathic Scoliosis
Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases
SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC
Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases
Quality of Life (HRQoL) of AIS Patients Who Require Bracing or Surgery Using SRS-22 Questionnaire
SRS Sequential Sindilimab in Brain Metastasis of NSLSC